Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization

Pharmaceutical Research

Volumn 20, Issue 7, 2003, Pages 969-977

  Maa, Yuh Fun ^a,b   Shu, Cassandra ^a,c   Ameri, Mahmoud ^a,b   Zuleger, Cindy ^a   Che, Jenny ^a   Osorio, Jorge E ^a   Payne, Lendon G ^a   Chen, Dexiang ^a  

^a PowderJect Vaccines Inc   (United States)

^b ALZA CORPORATION   (United States)

^c CELL GENESYS INC   (United States)

Author keywords

Alum adjuvant; Epidermal immunization; HBsAg; Powder formulation; Spray freeze drying; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; DEXTRAN; DIPHTHERIA TETANUS TOXOID; DODECYL SULFATE SODIUM; HEPATITIS B SURFACE ANTIGEN; MANNITOL; TREHALOSE; VACCINE;

ADSORPTION; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMISTRY; COMPRESSION; CONTROLLED STUDY; DENSITY; DRUG FORMULATION; DRUG STABILITY; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; EPIDERMIS; EXCIPIENT COMPATIBILITY; FEMALE; FREEZE DRYING; GUINEA PIG; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; METABOLISM; METHODOLOGY; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POWDER; PREFORMULATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; SCANNING ELECTRON MICROSCOPY; SEDIMENTATION; SKIN GRANULOMA; SKIN MANIFESTATION; SWINE; VACCINATION REACTION;

ADSORPTION; ALUM COMPOUNDS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; EPIDERMIS; FEMALE; GUINEA PIGS; IMMUNIZATION; MALE; POWDERS; VACCINES;

EID: 0038537336     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024493719236     Document Type: Article

References (29)

1. A. T. Glenny, C. G. Pope, H. Waddington, and U. Wallace. Antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29:38-45 (1926).
2. R. K. Gupta. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32:155-172 (1998).
3. R. G. White. Concepts relating to the mode of action of adjuvants. Symp. Set. Immunobiol. Stand. 6:3-12 (1967).
4. D. Chen. Y-F, Maa, and J. Haynes. Needle-free epidermal powder immunizations. Expert Vaccine Rev. 1:265-276 (2002).
5. A. F. Charest, J. McDougall, and M. B. Goldstein. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am. J. Kidney Dis. 36:976-982 (2000).
6. A. Egemen, S. Aksit, Z. Kurugol, S. Erensoy, A. Bilgic, and M. Akilli. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 16:1511-1515 (1998).
7. A. Sabchareon, P. Chantavanich, S. Pasuralertsakul, C. Pojjaroen-Anant, V. Prarinyanupharb, P. Attanath, V. Singhasivanon, W. Buppodom, and J. Lang. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr. Infect. Dis. J. 17:1001-1007 (1998).
8. M. Vogelbruch, B. Nuss, M, Korner, A. Kapp, P. Kiehl, and W. Bohm. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 55:883-887 (2000).
9. A. C. Pembroke and R. H. Marten. Unusual cutaneous reactions following diphtheria and tetanus immunization. Clin. Exp. Dermatol. 4:345-348 (1979).
10. D. Chen, R. L. Endres, C. A. Erickson, K. F. Weis, M. W. McGregor, Y. Kawaoka, and L. G. Payne. Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice. Nature Med. 6:1187-1190 (2000).
11. D. Chen, C. A. Erickson, R. L. Endres, S. B. Periwal, Q. Chu, C. Shu, Y.-F. Maa, and L. G. Payne. Adjuvantation of epidermal powder immunization. Vaccine 19:2908-2917 (2001).
12. D. Chen, K. Weis, A. Bucklen, C. A. Erickson, R. L. Endres, C. Lively, and L. G. Payne. Epidermal powder immunization induces both cytotoxic T lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. 75:11630-11640 (2001).
13. D. Chen, C. Y. Zuleger, Q. Chu, Y.-F. Maa, J. Osorio, and L. G. Payne. Epidermal powder immunization with recombinant HIV gp120 induces both humoral and cellular immune responses in mice. AIDS Res. Hum. Retroviruses 18:715-722 (2002).
14. M. I. Zapata, J. R. Feldkamp, G. E. Peck, J. L. White, and S. L. Hem. Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels. J. Pharm. Sci. 73:3-8 (1984).
15. Y.-F. Maa, L. Zhao, L. G. Payne, and D. Chen. Stabilization of alum-adjuvanted vaccine powder formulation: Mechanism and application. J. Pharm. Sci. 92:319-332 (2003).
16. D. Diminsky, N. Moav, M. Gorecki, and Y. Barenhol. Physical, chemical, and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18:3-17 (1999).
17. M. Kyosuke, I. Yoshimitsu, K. Tetsuo, and O. Nobuya. Hepatitis B vaccine and method for its preparation. European Patent #0130619 (1989).
18. Z. Csizer, K. Sikos, L. Bacskai, E. Niedermayer, L. Rethy, and J. Zsidai. Process for the preparation of lyophilized, adsorbed polyvalent vaccines. United States Patent #4,578,270 (1986).
19. H. Costantino, L. Firouzabadian, K. Hogeland, C. Wu, C. Beganski, K. Carrisquilla, M. Cardova, K. Griebenow, S. Zale, and M. Tracy. Protein spray freeze drying. Effect of atomization conditions on particle size and stability. Pharm. Res. 17:1374-1381 (2000).
20. Y.-F. Maa, P.-A. Nguyen, T. Sweeney, S. J. Shire, and C. C. Hsu. Protein inhalation powder: Spray drying vs. spray freeze drying. Pharm. Res. 16:249-254 (1999).
21. Y.-F. Maa and P.-A. Nguyen. Method of spray freeze drying proteins for pharmaceutical administration. United States Patent #6,282,282 (2001).
22. Y.-F. Maa and S. Prestrelski. Biopharmaceutical powders: Particle formation and formulation considerations. Curr. Pharm. Biotechnol. 1:283-302 (2000).
23. C. Sonner, Y.-F. Maa, and G. Lee. Spray-freeze-drying for protein powder preparation: Particle characterization and a case study with trypsinogen stability. J. Pharm. Sci. 91:2122-2139 (2002).
24. S. D. Allison, M. C. Manning, T. W. Randolph, K. Middleton, A. Davis, and J. F. Carpenter. Optimization of storage conditions of lyophilized actin using combination of disaccharides and dextran. J. Pharm. Sci. 89:199-214 (2000).
25. S. J. Prestrelski, N. Tedeschi, T. Arakawa, and J. F. Carpenter. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys. J. 65:661-671 (1993).
26. H. R. Costantino, J. D. Andya, P.-A. Nguyen, N. Dasovich, T. D. Sweeney, S. J. Shire, C. C. Chung, and Y.-F. Maa. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm Sci. 87:1406-1411.
27. H. Sueki, C. Gammal, K. Kudoh, and A. M. Kligman. Hairless guinea pig skin: anatomical basis for studies of cutaneous biology. Eur. J. Dermatol. 10:357-364 (2000).
28. H. Miyauchi and T. Horio. A new animal model for contact dermatitis: the hairless guinea pig. J. Dermatol. 19:140-145 (1992).
29. N. A. Monteiro-Riviere, D. G. Bristol, T. O. Manning, R. A. Rogers, and J. E. Riviere. Interspecies and interregional analysis of the comparative histologic thickness and laser Doppler blood flow measurements at five cutaneous sites in nine species. J. Invest. Dermatol. 95:582-586 (1990).